Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase III Randomized Trial of Pulse Actinomycin-D Versus Multi-Day Methotrexate for the Treatment of Low-Risk Gestational Trophoblastic Neoplasia.

Next Previous
Trial Profile

A Phase III Randomized Trial of Pulse Actinomycin-D Versus Multi-Day Methotrexate for the Treatment of Low-Risk Gestational Trophoblastic Neoplasia.

Status: Recruiting
Phase of Trial: Phase III

Latest Information Update: 18 Sep 2021

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Methotrexate (Primary) ; Methotrexate (Primary) ; Dactinomycin; Folinic acid
  • Indications Trophoblastic tumour
  • Focus Therapeutic Use

Most Recent Events

  • 13 Aug 2019 Biomarkers information updated
  • 12 Sep 2013 New source identified and integrated (Memorial Sloan-Kettering Cancer Center: 13-108).
  • 17 Jul 2013 New source identified and integrated (University Hospital Medical Information Network - Japan, UMIN000011154).

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top